ReNTOX Botulinum Toxin Type A REJURAN
Only wholesale. From 10 pieces minimum. We ship this drug in a cold case with dry ice and cold preservation.
Each 1 bottle contains 100 units of botulinum toxin type A.
Human serum albumin (EP) 0.5 mg
Sodium chloride (EP) 0.9 mg.
Description of ReNTOX
The drug is a lyophilized white powder for injection, in a colorless transparent bottle, when diluted with saline, it is a clear liquid.
Muscle relaxant of peripheral action, which contains purified botulinum toxin type A. The mechanism of action of the drug is based on the ability of botulinum toxin type A to block the transmission of nerve impulses. Intramuscular injection of toxin disrupts the synthesis of acetylcholine (a neurotransmitter that provides neuromuscular conduction) and leads to temporary paralysis of facial muscles. Reducing facial expression helps to relax the face and smooth out wrinkles.
Indications for use
Temporary improvement in the appearance of moderate to severe wrinkles associated with mimic activity in adult patients aged 18 to 65 years.
Indications for use:
mimic wrinkles in the forehead, between the eyebrows and the nasolabial triangle;
blepharospasm (involuntary contraction of the circular muscle of the eye);
horizontal and vertical neck wrinkles;
lip contour correction (botulinum toxin injections make the lip bend smoother).
The restrictions on the use of Botulax are the same as for other drugs based on botulinum toxin type A:
For blepharospasm the initial recommended dose is 1.25 - 2.5 U (0.05 mL to 0.1 mL volume at each site) injected into the medial and lateral pre-tarsal orbicularis oculi of the upper lid and into the lateral pre-tarsal orbicularis oculi of the lower lid. For pediatric cerebral palsy, a total dose of 4U/kg bodyweight is recommended for the affected gastrocnemius muscle in patients with hemiplegia. And in patients with diplegia, the recommended dose is 6U/kg bodyweight divided between both legs. The maximum dose administered must not exceed 200U/patient at a time. For Glabellar wrinkles reconstituted sterile saline. 20U is used and there are additional application instructions for best practice, actual amounts vary on the presentation of the client.
In Blepharospasm, the effects should appear within three days and peak after three weeks. For pediatric cerebral palsy applications, the expectation is improvement within four weeks of the injection. The effects vary for glabellar wrinkles due to the usually individualized dosages.
There is the possibility of reactions at the site of an injection, and effects beyond the injection site, including but not limited to asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. Serious hypersensitivity has been reported as rare. There is a caution for people with pre-existing neuromuscular disorders, and for those with corneal exposure and ulceration in blepharospasm. Botulium Toxin Type A is not to be administered at all if a patient has a known allergy to any of the ingredients, or if the patients have neuromuscular junctional disorders or known to have adverse reactions. They should not be administered while taking muscle relaxants and some antibiotics. Further, the actual effects of prolonged use are not entirely explored. There is also additional advice for the specific therapeutic conditions mentioned, as this description is not comprehensive.
In the case of overdose
In the case of an overdose it has been advised that effects may not be immediate. It is further advised that the patient be monitored for muscle weakness and/or paralysis for a period of weeks after the occurrence. There is an anti-toxin available but the caution with the anti-toxin is that it will not reduce any already apparent effects.
Place of Origin South Korea
Shelf Life 3 years in cold place